Wednesday, December 7, 2011

Vitamin K antagonists and prevention of thromboembolism

Posted by Chantel M. Contributed by US National Library of Medicine National Institutes of Health

In the study of "Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial" by Amadeus Investigators, Bousser MG, Bouthier J, B├╝ller HR, Cohen AT, Crijns H, Davidson BL, Halperin J, Hankey G, Levy S, Pengo V, Prandoni P, Prins MH, Tomkowski W, Torp-Pedersen C, Wyse DG., posted in US National Library of Medicine National Institutes of Health, found that in patients with atrial fibrillation at risk for thromboembolism, long-term treatment with idraparinux was no worse than vitamin K antagonists in terms of efficacy, but caused significantly more bleeding.

No comments:

Post a Comment